Schubert & Co’s Nektar Therapeutics NKTR Stock Holding History

Schubert & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	1542
2022 Q1	$0	Hold	1	–	–	﹤0.01%	1244
2021 Q4	$0	Buy	+1	New	+$217	﹤0.01%	1189

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Schubert & Co's NKTR Position: Q2 2022 in Review

Schubert & Co sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 1 share.

Schubert & Co first reported a position in NKTR in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Schubert & Co reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
Schubert & Co sold 1 Nektar Therapeutics share in Q2 2022.
Schubert & Co first reported a position in Nektar Therapeutics in Q4 2021 and held it in 2 quarters.
Schubert & Co's Nektar Therapeutics position peaked at $0 in Q1 2022.
227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Schubert & Co's 13F filing for Q2 2022, filed 1 Aug 2022.